SEC Form 4 · accession 0001553350-17-000019
HEAT BIOLOGICS, INC. · HTBX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ann A Rosar
Officer — VP of Finance
Period of report
Jan 2, 2016
Accepted (ET)
Jan 4, 2017 · 4:32 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001476963
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 2, 2017 | A | 70,000 | $0.00 | A | 70,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF2 | $0.88 | Jan 2, 2017 | A | 70,000 | A | Feb 1, 2017 | Jan 1, 2027 | Common Stock | 70,000 | 70,000 | D |
Explanation of responses
- F1The 70,000 shares of Heat Biologics, Inc. (the "Company") common stock, $0.0002 par value per share (the "Common Stock"), are represented by 70,000 restricted stock units ("RSUs") granted under the Company's Amended and Restated 2014 Stock Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of Common Stock. The 70,000 RSUs will vest as follows: (i) 17,500 will vest on January 2, 2017; (ii) 17,500 will vest on January 2, 2018; (iii) 17,500 will vest on January 2, 2019; and (iv) 17,500 will vest on January 2, 2020, provided that the reporting person is not terminated for cause prior to such dates.
- F2These stock options vest monthly on a pro rata basis over a four-year period with vesting commencing on February 1, 2017.